enGene Holdings Inc. (ENGN)

NASDAQ: ENGN · IEX Real-Time Price · USD
15.74
+0.14 (0.90%)
Apr 17, 2024, 4:30 PM EDT - Market closed
0.90%
Market Cap 685.97M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 43.58M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,687
Open 15.48
Previous Close 15.60
Day's Range 15.20 - 15.75
52-Week Range 6.69 - 47.17
Beta -0.49
Analysts Strong Buy
Price Target 35.50 (+125.54%)
Earnings Date Mar 11, 2024

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 31
Stock Exchange NASDAQ
Ticker Symbol ENGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ENGN stock is "Strong Buy." The 12-month stock price forecast is $35.5, which is an increase of 125.54% from the latest price.

Price Target
$35.5
(125.54% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

/C O R R E C T I O N -- enGene Inc./

In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by enGene Inc., the headline was incorrectly tr...

8 days ago - PRNewsWire

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

BOSTON and MONTREAL , April 9, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead produ...

8 days ago - PRNewsWire

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed pri...

5 weeks ago - PRNewsWire

enGene To Present at the Leerink Partners Global Biopharma Conference

BOSTON and MONTREAL , March 5, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is i...

6 weeks ago - PRNewsWire

enGene Announces Oversubscribed $200 Million Private Placement Financing

Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ ...

2 months ago - PRNewsWire

enGene Announces Leadership Succession Plan

BOSTON and MONTREAL , Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in ...

2 months ago - PRNewsWire

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial ...

2 months ago - PRNewsWire

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with interim data expected mid this year Completed a...

2 months ago - PRNewsWire

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

BOSTON and MONTREAL , Dec. 22, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unre...

Other symbols: HTGC
4 months ago - PRNewsWire

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

BOSTON and MONTREAL , Dec. 19, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsi...

4 months ago - PRNewsWire

enGene Appoints Ryan Daws as Chief Financial Officer

BOSTON and MONTREAL , Nov. 29, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study ...

5 months ago - PRNewsWire

Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company

CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion. Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive ...

5 months ago - Accesswire

enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company

Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non...

6 months ago - PRNewsWire